Navigation Links
FDA Warning Letter to Genzyme Related to the Allston Manufacturing Facility
Date:3/3/2009

Has No Foreseeable Impact on Aldurazyme Sales

NOVATO, Calif., March 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the FDA warning letter issued to Genzyme addressing deficiencies related to Genzyme's Allston Landing manufacturing facility during an inspection performed in September and October 2008 has no foreseeable impact on the supply of Aldurazyme. The warning letter does not require Genzyme to recall or quarantine product. BioMarin and Genzyme have sufficient quantities of finished product on hand to meet current demand and can fill additional product at a qualified alternate fill finish supplier. BioMarin is also qualifying a third supplier, which it expects to be approved later this year and has no concerns on maintaining sufficient levels of Aldurazyme inventory. BioMarin does not expect that the situation at the Allston manufacturing facility will have any impact on Aldurazyme sales.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the fill finish production of Aldurazyme and the expectations of revenue and sales related to Aldurazyme. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: future possible complications with the manufacture of or supply chain for Aldurazyme; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contact:

    Investors:                                  Media:
    Eugenia Shen                                Susan Berg
    BioMarin Pharmaceutical Inc.                BioMarin Pharmaceutical Inc.
    (415) 506-6570                              (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Campaign for Americas Future Memorandum: Katrina Storm Warning
2. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
3. Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
4. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
5. Defib Wire Warning Shouldnt Worry Most Users: Experts
6. India, UK Join Growing List of Countries to Require Pictorial Tobacco Warnings
7. Thoratecs ITC Division Receives FDA Warning Letter
8. FDA Issues New Warnings for Anemia Drugs
9. Warning for women who binge drink
10. Avandia Label to Get Heart-Attack Warning
11. FDA Mulls Tougher Warning Label on Kids Flu Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, ... with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week Hackathon ... 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every organization ...
(Date:7/20/2017)... Falls Church, VA (PRWEB) , ... July 20, ... ... Improve Your Bottom Line, **An FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. ... a secret weapon to passing inspections and boosting quality. , It’s known as ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Business Architecture Guild® ... Knowledge (BIZBOK® Guide )v 6.0 is now available for member download. This release ... collaborative teams. , Non-members may download the Part 1 Introduction for free ...
(Date:7/20/2017)... ... July 19, 2017 , ... A local summer theatre ... funds raised to support fine arts programs in Chester County’s Elementary Schools. In ... University’s Loyd Auditorium. , More than 850 people attended the two performances, ...
(Date:7/20/2017)... ... 19, 2017 , ... Western University of Health Sciences College ... grant to train predoctoral dental students in providing care to vulnerable children ages ... , The Predoctoral Pediatric Training Project (PPTP), a five-year grant, recognizes the curriculum ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... July 10, 2017  The tenth annual BioPharm ... MA at the Sheraton Boston Hotel, September ... access to global decision makers and innovative biotech startup ... science leaders during two impactful days. BioPharm America is ... with additional networking opportunities with 4,500+ life science industry ...
(Date:7/5/2017)... of over 2,000 employees and a leader in environmental and life science testing, ... position as the top American owned and operated environmental testing firm in ... ... The ... , enhances Pace Analytical,s capability as an innovative full service provider in the ...
(Date:6/30/2017)... POINT, N.C. , June 29, 2017  Axium Pharmaceuticals Inc. ... for developing improved novel formulations and alternative dosage forms of ... ... delivery is based on our waterless self-nano emulsifying formula, which ... contact with saliva. We believe the spray will provide fast ...
Breaking Medicine Technology: